Clinical Trial

Stellate Ganglion Stimulation for Restless Leg Syndrome in Hemodialysis Patients

Completed
View on ClinicalTrials.gov →
Summary
This randomized controlled trial investigated the effect of transcutaneous stellate ganglion electrical nerve stimulation (TENS-SG) on restless legs syndrome (RLS) in patients undergoing hemodialysis. Thirty-six patients aged 40-50 years were randomly assigned to two equal groups: Group A received active TENS-SG applied over the cervical-thoracic (stellate ganglion) region three times weekly for four weeks, while Group B received placebo stimulation. The study evaluated multiple outcomes including RLS severity (IRLS scale), sleep quality (PSQI), quality of life (SF-12), pain perception (pressure pain threshold), blood pressure, psychological status (HADS), and plasma β-endorphin levels. Results demonstrated that TENS-SG significantly reduced RLS severity and improved sleep quality, pain threshold, quality of life, and psychological well-being compared to placebo. It also significantly reduced systolic and diastolic blood pressure and markedly increased β-endorphin levels. Overall, the findings suggest that TENS-SG is a safe, non-invasive, and effective intervention for improving neurological, cardiovascular, psychological, and quality-of-life outcomes in hemodialysis patients with RLS.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-06-15.
Trial Details
NCT Number NCT07657013
Lead Sponsor Cairo University
Conditions Restless Leg Syndrome (RLS), Hemodialysis
Enrollment 36 participants
Start Date 2025-10-10
Primary Completion 2026-03-10 (estimated)
Study Completion 2026-05-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-22